Rutgers RWJMS Project ECHO
Maternal Child Health and Opioid Use Disorder (MCH-OUD) Caring for Pregnant People and Parenting Families ECHO

Provided by Rutgers Project ECHO & New Jersey Medical School Department of Gynecology & Obstetrics

Target Audience

This activity is designed for a cohort of practice teams, including Obstetric, Pediatric, Family Medicine (physicians, mid-levels and other team members as available), and social workers, emergency department staff, and behavioral health and addiction medicine providers throughout New Jersey who treat pregnant and parenting people with substance use disorders.

Learning Objectives

After participating in ECHO, participants should be better able to:

- Identify potential substance use problems using screening protocols during pregnancy;
- Explain evidence-based diagnostic and treatment approaches for people with substance use during pregnancy and newborn infants exposed to substances;
- Discuss care coordination for pregnant people with substance use disorders and their newborns throughout the perinatal period (preconception, pregnancy, labor/delivery, intrapartum, postpartum);
- Recognize the stigma of mental health and substance use disorders
- Identify how and when to prescribe Buprenorphine after the X Waiver removal

Rutgers RWJMS Project ECHO Planning Committee

Kathy Dodsworth-Rugani, PhD
Ruben Nanez
Amy Fisher, MHA
Mary Bridgeman, PharmD
Damali Campbell-Oparaji, MD
Natalie Roche, MD
Ashley Figueroa, MPA
Suzanne Spernal, DNP
Quinn Ingemi, MA

Maternal Child Health and Opioid Use Disorder ECHO Session Leaders

- Damali Campbell-Oparaji, MD, OBGYN, Rutgers New Jersey Medical School
- Natalie Roche, MD, OB/GYN, Rutgers New Jersey Medical School
- Quinn Ingemi, MA, LPC, Assistant Director, Behavioral Health, Perinatal Addictions Prevention Program, Southern New Jersey Perinatal Cooperative
- Lisa Lawson, MSW, MBA, LCSW, CCS, Director of Clinical and Integrated Health Catholic Charities, Diocese of Trenton

Accreditation

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

CME

Rutgers Biomedical and Health Sciences designates this live activity a maximum of 20 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Each session is designated for a maximum of 1 *AMA PRA Category 1 Credit*™.

CNE

This activity is awarded 20 ANCC contact hours. Each session is awarded a maximum of one contact hour.

Nurses should only claim those contact hours actually spent participating in the activity.

CPE

This application-based activity qualifies for 20 contact hours of continuing pharmacy education credit. Each session qualifies for a maximum of 1 contact hour of continuing pharmacy education credit.

Pharmacists should claim only those contact hours actually spent participating in this activity.

Social Workers

This program is approved for social work continuing education hours by Rutgers University Behavioral Health Care in accordance with New Jersey administrative code 13:44G-6.4 and recognized by The New Jersey Board of Social Work Examiners. This program is approved for 20.0 general social work continuing education hours.

Licensed and Certified Drug and Alcohol Counselors

This course will count for 20.0 recertification credits for Addiction Professionals as approved by The Certification board of NJ, Inc. Approval numbers for this course are:

Method of Participation

In order to receive CE credit, participants must register for the ECHO, and complete the evaluation and credit request at the conclusion of each session. Participants will receive one statement of credit from Rutgers Biomedical and Health Sciences at the conclusion of the series.

Pharmacists: Your official record of ACPE credit will be generated though the CPE Monitor System within 60 days following the conclusion of the ECHO. Your NABP e-Profile ID and date of birth will be collected through the evaluation and credit request. Please note that you must complete the evaluation and credit request for each session by the requested date. Under ACPE Policy, Rutgers Biomedical and Health Sciences (RBHS) will not be able to report your activity completion to CPE Monitor if your NABP e-Profile ID and date of birth are reported to and received by RBHS more than 60 days following the activity.

Peer Review Statement

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, this content has been reviewed by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by: Damali Campbell, MD, Quinn Ingemi, MA, Lisa Lawson, MSW, MBA, LCSW, CCS, and Natalie Roche, MD.

Disclosure Disclaimer

In accordance with the disclosure policies of RBHS and to conform with Joint Accreditation requirements and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any ineligible company, i.e., a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients, within the past 24 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Financial Disclosure Declarations

The following planning committee members and session leaders have no relevant financial relationships with ineligible companies to disclose:

Natalie Roche, MD (Planning Committee)
Damali Campbell-Oparaji, MD (Planning Committee)
Quinn Ingemi, MA (Planning Committee)
Ashley Figueroa, MPA (Planning Committee)
Kathy Dodsworth-Rugani, PhD (Planning Committee)
Suzanne Spernal, DNP (Planning Committee)
Amy Fisher, MHA (Planning Committee)
Ruben Nanez (Planning Committee)
Lisa Lawson, MSW, MBA, LCSW, CCS
Mary Bridgeman, PharmD (Planning Committee)

Off-label/Investigational Use Disclosure

Speakers are required to disclose discussion of off-label/investigational uses of commercial products. These disclosures will be made to the audience at the time of the activity.